Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: Stocks erase losses after Spanish auction

Tue, 28th Aug 2012 11:47

- Spanish bond auction lifts sentiment- Miners lower on concerns over Japan- Chemring drops profit warning.London's blue-chip index was trading broadly flat by midday, having erased all of the morning's losses, after a solid Spanish bond auction eased concerns about the heavily indebted Eurozone country.Miners were providing a drag on the FTSE 100 this morning on concerns about Japan, the world's third-largest economy. The Japanese government has reduced its view on personal consumption, housing construction, exports, imports and industrial output for the first 10 months of the year. "The Japanese economy is on the way to recovery at a moderate pace, partly due to reconstruction demand, while some weak movements are seen recently," the Cabinet Office said in its monthly report. JPMorgan Securities Japan and BNP Paribas are forecasting a 0.3% and 0.9% decline in third-quarter Japanese gross domestic product (GDP), respectively.Turning to Spain, the Treasury raised €3.607bn in short-term debt this morning, above the top-end of its target rage of €2.5-3.5bn. Borrowing costs dropped dramatically and demand increased significantly compared with the previous auction in July. According to the country's national statistics institute, Spanish GDP declined at a 1.3% annual rate in the second quarter, compared with the initial estimate of a 1% contraction. Markets continue to wait official news from the European Central Bank (ECB) regarding its proposed bond-buying programme. However, analyst Craig Erlam from Alpari said that recent market chatter has shown some consistency: "There have been numerous reports recently that claim to have inside knowledge on the matter. While they all differ slightly, there is also a lot of consistency. Based on these reports, it looks likely that the ECB will target short term debt yields, which will include a non-fixed yield cap on Spanish and Italian bonds," he said.However, ECB member Jörg Asmussen has said over the weekend that the EFSF bailout fund must take the lead in the purchase of any sovereign debt before the ECB steps in. "The ECB council will continue to decide in full independence whether, when and how it will purchase bonds on the secondary market," he said.FTSE 100: Kingfisher, G4S and miners weigh on benchmark indexB&Q owner Kingfisher was the heaviest faller of the day after Bank of America Merrill Lunch downgraded its rating on the stock to 'underperform'. Security giant G4S fell after expressing disappointment over the problems related to its Olympics contract, saying that it will incur a £50m loss on the contract in the first half. Meanwhile, the company said that a restructuring of its overhead structure will lead the loss of 1,100 jobs. Nevertheless, the firm revealed that turnover at constant exchange rates rose 7.5% while profits were flat. Miners were firmly out of favour this morning on concerns over the Japanese economy. BHP Billiton fell after announcing the sale of its Yeelirrie uranium deposit in Western Australia to Cameco for $430m. BHP and sector peers ENRC, Kazakhmys and Vedanta were also lower after Morgan Stanley reduced its target price for all four stocks. Drugs giant AstraZeneca was lower after saying that it has appointed Roche's Chief Operating Officer as its new Chief Executive Officer. Meanwhile, the firm also announced that the European Commission has granted marketing authorisation to its ZINFORO treatment. Sector peer GlaxoSmithKline was suffering from a downgrade by UBS.Bunzl, the international distribution and outsourcing group, fell despite saying that pre-tax profits and revenues in the first half rose 9% and 7%, respectively. FTSE 250: Chemring drops after profit warningDefence contractor Chemring dropped after it issued a profits warning, saying a computer glitch and production delays are likely to wipe £15m off full-year earnings as it considers a takeover offer from private equity giant Carlyle.Heading the other way was chemicals group Yule Catto after reporting a pre-tax profit of £56m in the first half, up from £52.4m the year before. Sales, however, fell to £603.3m from £664.3m.FTSE 100 - RisersITV (ITV) 85.00p +1.74%Carnival (CCL) 2,128.00p +1.72%Barclays (BARC) 190.20p +1.60%CRH (CRH) 1,149.00p +1.59%Fresnillo (FRES) 1,606.00p +1.52%Capital Shopping Centres Group (CSCG) 332.90p +1.22%United Utilities Group (UU.) 719.50p +1.20%BT Group (BT.A) 217.50p +1.07%Sainsbury (J) (SBRY) 332.60p +0.94%Glencore International (GLEN) 370.00p +0.86%FTSE 100 - FallersKingfisher (KGF) 275.60p -3.54%Evraz (EVR) 239.70p -2.88%Kazakhmys (KAZ) 642.00p -2.80%G4S (GFS) 259.10p -2.67%Eurasian Natural Resources Corp. (ENRC) 330.50p -2.48%Bunzl (BNZL) 1,084.00p -2.43%Vedanta Resources (VED) 906.00p -2.00%Marks & Spencer Group (MKS) 364.30p -1.99%IMI (IMI) 840.50p -1.93%InterContinental Hotels Group (IHG) 1,587.00p -1.79%FTSE 250 - RisersYule Catto & Co (YULC) 152.80p +7.76%Moneysupermarket.com Group (MONY) 138.10p +5.42%Ted Baker (TED) 1,000.00p +3.41%Renishaw (RSW) 1,568.00p +2.55%Dialight (DIA) 1,099.00p +2.33%Imagination Technologies Group (IMG) 578.50p +2.12%Home Retail Group (HOME) 95.15p +2.04%Homeserve (HSV) 216.30p +1.93%St. Modwen Properties (SMP) 202.40p +1.71%COLT Group SA (COLT) 119.20p +1.71%FTSE 250 - FallersChemring Group (CHG) 324.00p -12.55%Bumi (BUMI) 335.30p -5.55%Heritage Oil (HOIL) 191.00p -4.45%Cairn Energy (CNE) 285.10p -3.78%BTG (BTG) 310.30p -2.64%Afren (AFR) 126.80p -2.39%Cape (CIU) 188.50p -2.38%Bwin.party Digital Entertainment (BPTY) 92.90p -2.26%Perform Group (PER) 372.00p -2.11%NMC Health (NMC) 193.00p -2.03%BC
More News
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.